Brooks Laboratories Ltd

Brooks Lab's historical performance shows a recovery in net sales from 63.20 Cr in Mar'23 to 82.56 Cr in Mar'25, alongside improved operating profit of 4.94 Cr, despite a consolidated net loss of -9.97 Cr in Mar'25. Total assets increased to 123.69 Cr, and cash flow from operations turned positive at 2.00 Cr, indicating a potential turnaround.

As of 28-Oct, Brooks Laboratories Ltd is facing a significant decline in its stock price, currently at Rs 106.70, down 5.45% and 42.31% year-to-date, while underperforming compared to the Sensex, which has gained 8.30% this year. Despite increased investor participation, the stock remains in a bearish trend, trading below key moving averages.

Brooks Lab's historical performance shows fluctuating trends, with net sales rising from 63.20 Cr in March 2023 to 82.56 Cr in March 2025, and operating profit improving from -26.42 Cr to 4.94 Cr. However, the company still reported a net loss of -9.97 Cr in March 2025 and increasing liabilities.

As of 24-Oct, Brooks Laboratories Ltd's stock price has declined to Rs 114.50, down 6.11%, and has underperformed its sector. The stock is trading below all major moving averages and has seen a significant year-to-date decline of 38.09%, contrasting with the Sensex's positive performance.

As of October 20, 2025, Brooks Lab. is considered overvalued with a high PE ratio of 173.77 and an EV to EBITDA of 46.27, alongside poor financial performance and a year-to-date stock decline of 35.25%, making it an unfavorable investment at its current price of 119.75.

As of 20-Oct, Brooks Laboratories Ltd's stock price is Rs 119.75, down 3.15%, and it has significantly underperformed its sector and the broader market. The stock is in a bearish trend, trading below all major moving averages, with a year-to-date decline of 35.25% and reduced investor participation.

As of 07-Oct, Brooks Laboratories Ltd's stock price is Rs 129.25, down 1.07%, and has fallen 4.47% over the last two days. The stock is underperforming significantly compared to the broader market, with a year-to-date decline of 30.12%.

As of 26-Sep, Brooks Laboratories Ltd's stock price is Rs 139.95, down 1.62%, with a total decline of 4.57% over the last two days. Despite a significant increase in net profit, the stock's weak fundamentals and high valuation are deterring investors amid broader market underperformance.

As of 24-Sep, Brooks Laboratories Ltd is priced at 146.65, showing a slight increase today but has underperformed significantly year-to-date with a decline of 20.71%. Despite a recent gain, the stock's delivery volume has dropped sharply, indicating reduced investor interest and ongoing volatility.

As of 23-Sep, Brooks Laboratories Ltd's stock price is declining at 145.95, down 1.08%, with a total drop of 8.21% over the past six days. Despite strong recent earnings, the stock's weak long-term fundamentals and underperformance relative to the market indicate cautious investor sentiment.

As of 22-Sep, Brooks Laboratories Ltd's stock price is declining at 147.55, down 0.27%, with a total drop of 7.2% over the last five days. Despite strong recent profit growth, the stock faces downward pressure due to weak long-term fundamentals and high valuation metrics.

As of 19-Sep, Brooks Laboratories Ltd's stock price is Rs 147.95, down 0.7%, and has declined 6.95% over the last four days. Despite strong recent profit growth, the stock faces weak long-term fundamentals and poor short-term performance, underperforming the market significantly.